Active treatment of hemodynamically significant patent ductus arteriosus (PDA) in preterm infants within the first 2 weeks of life was associated with worse outcomes than expectant management.

Incidence of death or BPD does not differ with expectant management versus active treatment for preterm infants with protocol-defined PDA.

Patent ductus arteriosus (PDA) remains a prominent clinical challenge in the management of preterm infants. During fetal life, the ductus arteriosus diverts blood away from the underdeveloped lungs, ...

Please provide your email address to receive an email when new articles are posted on . Compared with surgical ligation, transcatheter closure of the patent ductus arteriosus in infants and neonates ...

Credit: Getty Images. Evidence suggests that patent ductus arteriosus comprises anywhere from 5% to 10% of all congenital heart disease. Although the majority of congenital heart diseases (CHD) are ...

An estimated 40 percent of this group will die before the age of 2. However, little is known about what causes the development of BPD-PH. “Current screening methods are limited in their ability to ...

The Society for Cardiovascular Angiography & Interventions (SCAI) has published a new position statement that provides best-practice guidance for the treatment of patent ductus arteriosus (PDA) using ...

First and only delivery system designed specifically for premature infants with a patent ductus arteriosus (PDA), a life-threatening opening in their heart New delivery ...

Abbott has secured the US Food and Drug Administration (FDA) and CE Mark approvals for its Amplatzer Piccolo delivery system, ...

Objective: To provide commentary and reviews and brief discussions in controversial or innovative recent advances in neonatal pharmacotherapy. To discuss cutting edge drug delivery systems that may ...